SCHEMBL4240910

SCHEMBL4240910

Nc1ccc(N2CCN(Cc3c[nH]nc3-c3ccc(F)cc3)CC2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
DRD3 P35462 9/20 0.42
DRD2 P14416 8/20 0.42
DRD4 P21917 7/20 0.42
OPRM1 P35372 1/20 0.41
OPRK1 P41145 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTR1A P08908 3/20 0.40
HTR2A P28223 3/20 0.40
SLC6A4 P31645 2/20 0.40
DRD1 P21728 3/20 0.40
DRD5 P21918 3/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4248577 0.87 MAPT (0.45) MAPTDRD3DRD2DRD4OPRM1
SCHEMBL4246582 0.87 DRD3 (0.54) MAPTDRD3DRD2DRD4OPRM1
SCHEMBL4400914 0.87 DRD2 (0.52) MAPTDRD3DRD2DRD4OPRM1
SCHEMBL4245287 0.87 MAPT (0.42) MAPTDRD3DRD2DRD4OPRM1
SCHEMBL4252387 0.86 SMN1; SMN2 (0.53) MAPTDRD4KDM4EL3MBTL1LMNA
SCHEMBL4245098 0.85 OPRM1 (0.45) MAPTDRD3DRD2DRD4OPRM1
SCHEMBL4245772 0.85 OPRM1 (0.62) DRD3DRD2DRD4OPRM1OPRK1
SCHEMBL4248465 0.85 SMO (0.46) MAPTDRD3DRD2DRD4KDM4E
SCHEMBL4246703 0.84 OPRM1 (0.50) MAPTDRD3DRD2DRD4OPRM1
SCHEMBL4245353 0.83 MAPT (0.53) MAPTDRD3DRD2DRD4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US claimed
CN-101490010-A Compounds and compositions as ITPKB inhibitors IRM LLC (VG) 2009-07-22 CN claimed
EP-2057124-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM, LLC (BM) 2009-05-13 EP claimed
WO-2008011611-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2008-01-24 WO claimed
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US disclosed
CN-101490010-A Compounds and compositions as ITPKB inhibitors IRM LLC (VG) 2009-07-22 CN disclosed
EP-2057124-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM, LLC (BM) 2009-05-13 EP disclosed
WO-2008011611-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IP6K1, IP6K2, IP6K3 MAPT 3880/4885DRD3 4698/4885DRD2 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.